Bayer faces Missouri trial over Roundup cancer claims

Three cancer patients began a trial against Bayers Monsanto unit in Missouri on Tuesday. The plaintiffs argue that Roundup was defectively designed and inadequately tested. This case tests claims not barred by a recent US Supreme Court ruling.

Xurve View
Insights:
FILE PHOTO: Bottles of Roundup, a brand owned by Bayer, are seen for sale in a store in Manhattan, New York City, U.S., June 30, 2022. REUTERS/Andrew Kelly/File Photo

BAYER AG-REG faces a Missouri jury trial over its Roundup weedkiller on Tuesday afternoon, testing design-defect claims after a favorable United States Supreme Court ruling. The litigation has pressured the German company since its 2018 acquisition of Monsanto, reducing its share price and costing billions of dollars. The case could determine the viability of remaining claims as the company pursues a $7.25 billion class action settlement.